Selected Reading

Abraham E, Evans T. Corticosteroids and septic shock. (Editorial) JAMA 2002;288(7):886-7

Al-Hazmi M, Ayoola EA, Abdurahman M, et al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. Clin Infect Dis 2003 Feb 1;36(3):245-52

Allela L, Bourry O, Pouillot R, et al. Ebola virus antibody prevalence in dogs and human risk. Emerg Infect Dis 2005 Mar;11(3):385-90

Alsop Z. Ebola outbreak in Uganda "atypical," say experts. Lancet 2007 Dec 22;370(9605):2085

Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002:288(7):862-71

Anyamba A, Chretien J-P, Formenty PBH, et al. Rift Valley fever potential, Arabian Peninsula. (Letter) Emerg Infect Dis 2006 Mar;12(3):518-20

Armstrong LR, Dembray LM, Rainey PM, et al. Management of a Sabia virus-infected patient in a US hospital. Infect Control Hosp Epidemiol 1999;20:176-82

ASM. Sentinel laboratory guidelines for suspected agents of bioterrorism: packing and shipping infectious substances, diagnostic specimens, and biological agents.

ASM. Sentinel laboratory guidelines for suspected agents of bioterrorism: unknown viruses

Aufiero P, Karabulut N, Rumowitz D, et al. Imported Lassa fever: New Jersey, 2004. (Case report) JAMA 2004 Dec 15;292(23):894-7

Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008 Jun 1;197(11):1577-84

Bae HG, Nitsche A, Teichmann A, et al. Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay. J Virol Methods 2003;110(2):185-91

Banerjee K, Gupta NP, Goverdhan MK. Viral infections in laboratory personnel. Indian J Med Res 1979;69:363-73

Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Expert Rev Vaccines 2008 Jul;7(5):579-87

Barrientos LG, Rollin PE. Release of cellular proteases into the acidic extracellular milieu exacerbates Ebola virus-induced cell damage. Virology 2007 Feb 5;358(1):1-9

Barrier Products, LLC. BioSeal Facility System

Barry M, Russi M, Armstrong L, et al. Brief report: treatment of a laboratory acquired Sabia virus infection. N Engl J Med 1995;333:294-6

Bausch DG, Borchert M, Grein T, et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 2003 Dec;9(12):1531-7

Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006 Aug 31;355(9):909-19

Bausch DG, Sprecher AG, Jeffs B, et al. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res 2008 (published online Feb 26)

Belsher JL, Gay P, Brinton M, et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007 Dec 5;25(50):8480-5

Bermejo M, Rodriguez-Teijeiro JD, Illera G, et al. Ebola outbreak killed 5,000 gorillas. Science 2006 Dec 8;314(5805):1564

Bharaj P, Chahar HS, Pandey A, et al. Concurrent infections by all four dengue virus serotypes during an outbreak of 2006 in Delhi, India. Virol J 2008 Jan 9;5:1

Biek R, Walsh PD, Leroy EM, et al. Recent common ancestry of Ebola Zaire virus found in a bat reservior. PLoS Pathog 2006;2(10):e90

Bird BH, Albarino CG, Nichol ST. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 2007 May 25;362(1):10-15

Birmingham K, Cooney S. Ebola: small, but real progress. Nat Med 2002 Apr;8(4):313

Borchert M, Mulangu S, Swanepoel R, et al. Serosurvey on household contacts of Marburg virus. Emerg Infect Dis 2006 Mar;12(3)

Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons. JAMA 2002;287(18)

Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003 Dec 1;188(11):1630-8

Bowen MD, Rollin PE, Ksiazek TG, et al. Genetic diversity among Lassa virus strains. J Virol 2000;74(15):6992-7004

Brandler S, Lucas-Hourani M, Moris A, et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007 Dec 12;1(3):e96

Bray M. Defense against filoviruses used as biological weapons. Antiviral Res 2003 Jan;57(1-2):53-60

Bredenbeek PJ, Molenkamp R, Spaan WJ, et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006 Feb 20;345(2):299-304

Britch SC, Linthicum KJ, Rift Valley Fever Working Group. Developing a research agenda and a comprehensive national prevention and response plan for Rift Valley fever in the United States. Emerg Infect Dis 2007 Aug;13(8):e1

Brunkard JM, Robles Lopez JL, Ramirez J, et al. Dengue fever seroprevalence and risk factors, Texas-Mexico border, 2004. Emerg Infect Dis 2007 Oct;13(10):1477-83

Bryant J, Want H, Cabezas C, et al. Enzootic transmission of yellow fever virus in Peru. Emerg Infect Dis 2003 Aug;9(8):626-33

Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007 Jun;81(12):6379-88

Bukreyev A, Yang L, Zaki SR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006 Mar;80(5):2267-79

Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999 Feb;179(Suppl 1):S1-S7

Caceda ER, Kochel TJ. Application of modified shell vial culture procedure for arbovirus detection. PLoS ONE 2007 Oct 17;2(10):e1034

Carey DE, Kemp GE, White HA, et al. Lassa fever: epidemiologic aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg 1972;66:402-8

Carrion R Jr, Patterson JL, Johnson JL, et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 2007 May 16;25(20):4093-102

Casillas AM, Nyamathi AM, Sosa A, et al. A current review of Ebola virus: pathogenesis, clinical presentation, and diagnostic assessment. Biol Res Nurs 2003 Apr;4(4):268-75

CDC. Adverse events associated with 17D-derived yellow fever vaccination—United States, 2001-2002. MMWR 2002 Nov 8;51(44):989-93

CDC. Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC strategic planning workgroup. MMWR 2000:49(RR04):1-14

CDC. Biosafety in microbiological and biomedical laboratories (BMBL). Ed 4, April 1999

CDC. Bolivian hemorrhagic fever?El Beni Department, Bolivia, 1994. MMWR 1994;43(50):943-6

CDC. Brief report: outbreak of Marburg Virus hemorrhagic fever--Angola, October 1, 2004-March 29, 2005. MMWR 2005 Mar 30;54(Dispatch):1-2

CDC. Dengue hemorrhagic fever--U.S.-Mexico border, 2005. MMWR 2007 Aug 10;56(31):785-9

CDC. Ebola hemorrhagic fever in the Republic of the Congo. Released May 20, 2005

CDC. Ebola-Reston virus infection among quarantined nonhuman primates?Texas, 1996. MMWR 1996;45(15);314-6

CDC. Epidemiologic notes and reports update: Ebola-related filovirus infection in nonhuman primates and interim guidelines for handling nonhuman primates during transit and quarantine. MMWR 1990;39(2):22-24, 29-30

CDC. Fatal illness associated with a New World arenavirus?California, 1999-2000. MMWR 2000;49(31);709-11

CDC. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR 2001;50(30):643-5

CDC. Filovirus infection associated with contact with nonhuman primates or their tissues. MMWR 1990;39(24):404-5

CDC. Filovirus infections among persons with occupational exposure to nonhuman primates or their tissues. MMWR 1990;39(16):266,273

CDC. Hantavirus pulmonary syndrome: five states, 2006. MMWR 2006 Jun 9;55(22):627-9

CDC. Imported Lassa fever: New Jersey, 2004. MMWR 2004 Oct 1;53(38):894-7

CDC. Infection control for viral haemorrhagic fevers in the African health care setting. 2005

CDC. Interim guidance about Marburg virus infection for airline flight crews, cargo and cleaning personnel, and personnel interacting with arriving passengers. Released Apr 13, 2005, and updated as necessary

CDC. Interim guidance about Marburg virus infection for U.S. Citizens living abroad. Apr 14, 2005

CDC. Laboratory Response Network for bioterrorism

CDC. Laboratory security and emergency response guidance for laboratories working with select agents. MMWR 2002 Dec 6;51(RR-19):1-6

CDC. Management of patients with suspected viral hemorrhagic fever. MMWR 1988;37(S-3):1-16

CDC. Management of patients with suspected viral hemorrhagic fever?United States. MMWR 1995;44(25):475-9

CDC. Marburg Hemorrhagic Fever Home Page

CDC. Marburg virus hemorrhagic fever, Angola, Central Africa interim guidance for humanitarian workers. Released Apr 5, 2005; updated as necessary

CDC. Medical examiners, coroners, and biologic terrorism: a guidebook for surveillance and case management. MMWR 2004 Jun 11;53(RR08):1-36

CDC. Official health advisory: Imported Lassa fever case in New Jersey. Sep 3, 2004

CDC. Outbreak of Ebola hemorrhagic fever?Uganda, August 2000?January 2001. MMWR 2001:50(05):73-7

CDC. Outbreak of Marburg virus hemorrhagic fever: Angola, October 1, 2004 - March 29, 2005. MMWR 2005 Apr 1;54(12):308-9

CDC. Outbreak of Rift Valley fever?Saudi Arabia, August-November 2000. MMWR 2000;49(43);982-5

CDC. Outbreak of Rift Valley fever?Yemen, August?October 2000. MMWR 2000;49(47):1065-6

CDC. Rift Valley fever outbreak--Kenya, November 2006-January 2007. MMWR 2007 Feb 2;56(4):73-6

CDC. Rift Valley fever?East Africa, 1997-1998. MMWR;47(13):261-4

CDC. Select Agent Program

CDC. Travel-associated dengue: United States, 2005. MMWR 2006 Jun 30;55(25):700-2

CDC. Travelers' health outbreak notice: Marburg virus hemorrhagic fever: Angola, Central Africa. Updated Jul 29, 2005

CDC. Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR 2002 Nov 8;51(RR17):1-10

Cevik MA, Erbay A, Bodur H, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 2007 (published online Dec 6)

Chance JJ, Li DJ, Sokoll LJ, et al. Multiple site analytical evaluation of a portable blood gas/electrolyte analyzer for point of care testing. Crit Care Med 2000;28(6):2081-5

Chandran K, Sullivan NJ, Felbor U, et al. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005 (published online Apr 14)

Chao D-Y, Lin T-H, Swang K-P, et al. 1988 Dengue hemorrhagic fever epidemic in Taiwan. (Letter) Emerg Infect Dis 2004 Mar;10(3):252-4

Charrel RN, Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res 2003 Jan;57(1-2):89-100

Chevalier V, Lancelot R, Thiongane Y, et al. Rift Valley fever in small ruminants, Senegal, 2003. Emerg Infect Dis 2005 Nov;11(11):1693-700

Ciota AT, Lovelace AO, Jia Y, et al. Characterization of mosquito-adapted West Nile virus. J Gen Virol 2008 Jul;89(7):1633-42

Conrad JL, Isaacson M, Smith EB, et al. Epidemiologic investigation of Marburg virus disease, Southern Africa, 1975. Am J Trop Med Hyg 1978;27(6):1210-5

Cunha BA. Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room. Clin Microbiol Rev 2002 Aug 8(8):489-503

Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 2006 Oct;80(19):9659-66

Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessement. Lancet 2006 Apr 29;367:1399-404

Dandawatte CN, Desai GB, Achar TR, et al. Field evaluation of formalin inactivated Kyasanur forest disease virus tissue culture vaccine in 3 districts of Karnataka state. Indian J Med Res 1994;99:152-8

Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever: an undescribed virus disease of sheep, cattle, and man from East Africa. J Pathol Bacteriol 1931;34:545-79

Davila JC, Payne DC, Zhang Y, et al. Quality assessment of nonanthrax vaccination data in the Defense Medical Surveillance System, 1998-2004. Vaccine 2008 Mar 17;26(12):1577-84

de Filippis AM, Nogueira RM, Schatzmayr HG, et al. Outbreak of jaundice and hemorrhagic fever in the Southeast of Brazil in 2001: detection and molecular characterization of yellow fever virus. J Med Virol 2002 Dec;68(4):620-7

Delgado S, Erickson BR, Agudo R, et al. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 2008 Apr 18;4(4):e1000047

Demby AH, J. Chamberlain J, Brown DW, et al. Early diagnosis of Lassa fever by reverse transcription-PCR. J Clin Microbiol 1994;32(12):2898-903

Dery M, Bausch DG. A DNA vaccine for the prevention of Ebola virus infection. Curr Opin Mol Ther 2008 Jun;10(3):285-93

Djavani MM, Crasta OR, Zapata JC, et al. Early blood profiles of virus infection in a monkey model for Lassa fever. J Virol 2007 Aug;81(15):7960-73

Dowling W, Thompson E, Badger C, et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J Virol 2007 Feb;81(4);1821-37

Drosten C, Gottig S, Schilling S, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, Dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002;40(7):2

Drosten C, Panning M, Guenther S, et al. False-negative results of PCR assay with plasma of patients with severe viral hemorrhagic fever. (Letter) J Clin Microbiol 2002 Nov;40(11):4394-5

Duh D, Nichol ST, Khristova ML, et al. The complete genome sequence of a Crimean-Congo hemorrhagic fever virus isolated from an endemic region in Kosovo. Virol J 2008 (published online Jan 15)

Duh D, Saksida A, Petrovec M, et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg Infect Dis 2007 Nov;13(11):1769-72

Dylla DE, Michele DE, Campbell KP, et al. Basolateral entry and release of New and Old World arenaviruses from human airway epithelia. J Virol 2008 Jun;52(6):2276-8

Effler PV, Pang L, Kitsutani P, et al. Dengue fever, Hawaii, 2001-2002. Emerg Infect Dis 2005 May;11(5)

Egger JR, Coleman P. Age and clinical dengue illness. Emerg Infect Dis 2007 Jun;13(6):924-5

Ellis BR, Barrett ADT. The enigma of yellow fever in East Africa. Rev Med Virol 2008 (published online Jul 10)

Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004 Mar 15;189(6):990-1000

Ergonul O, Celikba A, Dokuzoguz B, et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004 Jul 15;39(2):284-7

Faye O, Diallo M, Diop D, et al. Rift Valley fever outbreak with east-central African virus lineage in Mauritania, 2003. Emerg Infect Dis 2007 Jul;13(7):1016-23

Feldman H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007 Jan 19 3(1):e2

Feldmann H. Marburg hemorrhagic fever--the forgotten cousin strikes. N Engl J Med 2006 Aug 31;355(9):866-9

Feng Z, Cerveny M, Yan Z, et al. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol 2007 Jan;81(1):182-92

Fisher-Hoch SP, McCormick JB. Lassa fever vaccine. Expert Rev Vaccines 2004 Apr;3(2):189-97

Flanagan ML, Oldenburg J, Reignier T, et al. New World clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. J Virol 2008 Jan;92(2):938-48

Formenty P, Leroy EM, Epelboin A, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis 2006 Jun 1;42(11):1521-6

Francesconi P, Yoti Z, Declich S, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 2003 Nov;9(11):1430-7

Frank C, Schoneberg I, Krause G, et al. Increase in imported dengue, Germany, 2001-2002. Emerg Infect Dis 2004 May;10(5)

Gaspar LP, Mendes YS, Yamamura AM, et al. Pressure-activated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008 Jun;150(1):57-62

Geisber TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008 Jun;82(11):5664-8

Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003 Dec 13;362(9400):1953-8

Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005 Jun 28;2(6)

Geisbert TW, Pushko P, Anderson K, et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002 May;8(5):503-7

Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003 Dec 1;188(11):1618-29

Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003 Dec;163(6):2347-70

Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003 Dec;163(6):2371-82

Georges AJ, Leroy, EM, Renaut AA, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. J Infect Dis 1999 Feb:179(Suppl 1):S65-S75

Gerrard SR, Li L, Barrett AD, et al. Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol 2004 Aug;78(16):8922-6

Gibb TR, Norwood DA Jr, Woollen N, et al. Development and evaluation of a fluorogenic 5' nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan. J Clin Microbiol 2001;39(11):4125-30

Gibb TR, Norwood DA Jr, Woollen N, et al. Development and evaluation of a fluorogenic 5'-nuclease assay to identify Marburg virus. Mol Cell Probes 2001;15(5):259-66

Golovljova I, Vasilenko V, Mittzenkov V, et al. Characterization of hemorrhagic fever with renal syndrome caused by hantaviruses, Estonia. Emerg Infect Dis 2007 Nov;13(11):1773-6

Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008 Feb 9;371(9611):500-9

Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis. Antiviral Res 2003 Jan;57(102):129-46

Gubler DJ, Zaki SR. Dengue and other viral hemorrhagic fevers. In: Nelson AM, Horsburgh CR Eds. Pathology of Emerging Infections 2. Washington, DC: American Society of Microbiology Press, 1998:43-71

Guha-Sapir D, Schimmer B. Dengue fever: new paradigms for a changing epidemiology. Emerg Themes Epidemiol 2005 Mar 2;2(1)

Guimard Y, Bwaka MA, Colebunders R, et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999 Feb:179(Suppl 1): S268-S273

Gunther S, Weisner B, Roth A, et al. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum. J Infect Dis 2001;184(3):345-9

Guzman MG, Alvarez M, Rodriguez-Roche R, et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 2007 Feb;13(2) (published online Jan 11)

Haas WH, Breuer T, Pfaff G, et al. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis 2003 May 15:36(10):1254-8

Hart MK. Vaccine research efforts for filoviruses. International Journal for Parasitology 2003 May;33(5-6):583-95

Hartlieb B, Muziol T, Weissenhorn W, et al. Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proc Natl Acad Sci 2007 Jan 9;104(2):624-9

Hartman AL, Ling L, Nichol ST, et al. Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 2008 Jun;82(11):5348-58

Heffernan RT, Pambo B, Hatchett RJ, et al. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooue-Ivindo region, northeastern Gabon, 1997. J Infect Dis 2005 Mar 15;19(6):964-8

Hewlett BS, Amola RP. Cultural contexts of Ebola in Northern Uganda. Emerg Infect Dis 2003 Oct;9(10):1242-8

Heymann DL, Weisfeld JS, Webb PA, et al. Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978. J Infect Dis 1980 Sep;142(3):372-6

HHS. 42 CFR Part 73: Possession, use, and transfer of select agents and toxins. Interim Final Rule. Fed Reg 2002 Dec 13;240(67):76885-905

Holbrook MR, Aronson JF, Campbell GA, et al. An animal model for the tickborne flavivirus - Omsk hemorrhagic fever virus. J Infect Dis 2005 Jan 1;191(1):100-8

Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11(suppl 4):S750-S761

Hung NT, Lei H-Y, Lan NT, et al. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 2004 Jan 15;189(2):221-32

Hussain AI, Johnson JA, Da Silva Freire M, et al. Identification and characterization of avian retroviruses in chicken embryo-derived yellow fever vaccines: investigation of transmission to vaccine recipients. J Virol 2003 Jan;77(2):1105-11

Isaacson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis 2001;33(10):1707-12

ITAR_TASS News Agency. Ebola, lab accident death?Russia (Siberia). ProMED-mail 2004;May ; 20040522.1377

Jaax N, Jahrling P, Geisbert T, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995;346(8991-2):1669-71

Jaax NK, Davis KH, Geisber TJ, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996;120:140-55

Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999 Feb;179(Suppl 1):S224-S234

Jahrling PB. Filoviruses and arenaviruses. In: Murray PR, Baron EJ, Pfaller MA, et al, eds. Manual of clinical microbiology. Ed 7. Washington DC: American Society for Microbiology Press, 1999:1125-36

Jahrling PB. Viral hemorrhagic fevers. In: Zajtchuk R, Bellamy RF, eds. Textbook of military medicine: medical aspects of chemical and biological warfare. Chap 29. Washington, DC: Office of the Surgeon General, Borden Institute, Walter Reed Army Medical Center

Jaureguiberry S, Tattevin P, Tarantola A, et al. Imported Crimean-Congo hemorrhagic fever. J Clin Microbiol 2005 Sep;43(9):4908-10

Johnson E, Jaax N, White J, et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995;76(4):227-36

Johnson KM, McCormick JB, Webb PA, et al. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 1987 Mar;155(3):456-64

Jones KE, Patel NG, Levy MA, et al. Global trends in emerging infectious diseases. Nature 2008 Feb 21;451(7181):990-3

Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. (Letter) Nature Med 2005 Jul;11(7):786-90

Karesh WB, cook RA, Gilbert M, et al. Implications of wildlife trade on the movement of avian influenza and other infectious diseases. J Wildl Dis 2007 Jul;43(3 suppl):S55-9

Karti SS, Odabasi Z, Korten V, et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004 Aug;10(8):1379-84

Kawaoka Y. How Ebola virus infects cells. N Engl J Med 2005 Jun 23;352(25):2645-6

Kenyon RH, McKee KT Jr, Sack PM, et al. Aerosol infection of rhesus macaques with Junin virus. Intervirology 1992;33(1):23-31

Khan AS, Tshioko FK, Heymann DL, et al. The re-emergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. J Infect Dis 1999 Feb;179(Suppl 1):S76-86

Kibadi K, Mupapa K, Kuvula K, et al. Late ophthalmologic manifestations in survivers of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999 Feb;179(Suppl 1):S13-14

Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006 Mar 15;346(2):394-401

Koraka P, Zeller H, Niedrig M, et al. Reactivity of serum samples from patients with a flavivirus infection measured by immunofluorescence assay and ELISA. Microbes Infect 2002 Oct;4(12):1209-15

Kortepeter MG, Martin JW, Rusnak JM, et al. Managing potential laboratory exposure to Ebola virus by using a patient biocontainment care unit. Emerg Infect Dis 2008 Jun;14(6):881-7

Ksiazek TG, Rollin PE, Jahrling PB, et al. Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol 1992;30(4):947-50

Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999 Feb;179(Suppl 1):S177-S187

Ksiazek TG, West CP, Rollin PE, et al. ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 1999 Feb;179(Suppl 1):S192-S198

LaBeaud AD, Muchiri EM, Ndzovu M, et al. Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. Emerg Infect Dis 2008 Aug (published online Jul 23)

Lacy MD, Smego RA. Viral hemorrhagic fevers. Adv Pediatr Infect Dis 1996;12:21-53

Lateef A, Fisher DA, Tambyah PA. Dengue and relative bradycardia. (Letter) Emerg Infect Dis 2007 Apr;13(4) (published online Mar 21)

Lazaro ME, Cantoni GE, Calanni LM, et al. Clusters of hantavirus infection, southern Argentina. Emerg Infect Dis 2007 Jan;13(1) (published online Dec 1)

LeDuc JW. Epidemiology of hemorrhagic fever viruses. Rev Infect Dis 1989 May-Jun;11(Suppl 4):S730-5

Lee AM, Rojek JM, Spiropoulou CF, et al. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem 2008 Jul 4;283(27):18734-42

Lee E, Lobigs M. E Protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 2008 Jun;82(12):6024-33

Lee JE, Fusco ML, Hessell AJ, et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008 Jul 10;454(7201):177-82

Lefeuvre A, Marianneau P, Deubel V. Current assessment of yellow fever and yellow fever Vaccine. Curr Infect Dis Rep 2004 Apr;6(2):96-104

Leroy EM, Baize S, Lu CY, et al. Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol 2000 Apr;60(4):463-7

Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000;355(9222):2210-5

Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005 Dec 1;438(7068):575-6

Lisieux T, Coimbra M, Nassar ES, et al. New arenavirus isolated in Brazil. Lancet 1994;343(8894):391-2

Ljungberg K, Whitmore AC, Fluet ME, et al. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J Virol 2007 Dec;81(24):13412-23

Loeb M, MacPherson D, Barton M, et al. Implementation of the Canadian contingency plan for a case of suspected viral hemorrhagic fever. Infect Control Hosp Epidemiol 2003 Apr;24(4):280-3

Lucht A, Grunow R, Moller P, et al. Development, characterization and use of monoclonal VP40-antibodies for the detection of Ebola virus. J Virol Methods 2003 Jul;111(1):21-8

Lukashevich IS, Patterson J, Carrion R, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 2005 Nov;79(22):13934-42

Lunkenheimer K, Hufert FT, Schmitz H. Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction. J Clin Microbiol 1990;28(12):2689-92

Macher AM, Wolfe MS. Historical Lassa fever reports and 30-year clinical update. Emerg Infect Dis 2006 May;12(5):835-7

Madani TA, Al-Mazrou YY, Al-Heffri MH, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003 Oct 15;37(8):1084-92

Madani TA. Alkhumra virus infection, a new viral hemorrhagic fever in Saudi Arabia. J Infect 2005 Aug;51(2):91-7

Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003 Mar 15;170(6):2797-801

Mahanty S, Hutchinson K, Agarwal S, et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003 Mar 15;170(6):2797-802

Maher-Sturgess SL, Forrester NL, Wayper PJ, et al. Universal primers that amplify RNA from all three flavivirus subgroups. Virol J 2008 Jan;5(16) (published online Jan 24)

Manicassamy B, Wang J, Rumschlag E, et al. Characterization of Marburg virus glycoprotein in viral entry. Virology 2007 Feb 5;358(1):79-88

Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006 Nov;13(11):1267-77

McGee CE, Tsetsarkin K, Vanlandingham DL, et al. Substitution of wild-type yellow fever asibi sequences for 17D vaccine sequences in ChimeriVax-Dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 2008 (published online Feb 11)

Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD+8 T-cell responses to smallpox and yellow fever vaccines. Immunity 2008 May 16;28(5):710-22

Miranda ME, Ksiazek TG, Retuya TJ, et al. Epidemiology of Ebola (subtype Reston) in the Phillipines, 1996. J Infect Dis 1999;179(suppl 1):S115-S119

Morens DM, Fauci AS. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA 2008 Jan 9/16;299(2):214-6

Munoz J, Vilella A, Domingo C, et al. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J Travel Med 2008 May-Jun;15(3):202-5

Mutebi JP, Gianella A, da Rosa AT, et al. Yellow fever virus infectivity for Bolivian Aedes aegypti mosquitoes. Emerg Infect Dis 2004 Sep;10(9):1657-60

Ndayimirije N, Kindhauser MK. Marburg hemorrhagic fever in Angola: fighting fear and a lethal pathogen. (Perspective) N Engl J Med 2005 May 26;352(21):2155-7

Neumann G, Geisbert TW, Ebihara H, et al. Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol 2007 Mar;81(6):2995-8

Niedrig M, Kursteiner O, Herzog C, et al. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 2008 Feb;15(2):177-81

Niska RW, Burt CW. Training for terrorism-related conditions in hospitals: United States, 2003-04. Adv Data 2006 Dec 11;(380):1-9

Noda T, Watanabe S, Sagara H, et al. Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus. J Virol 2007 Apr;81(7):3554-62

Nyamathi AM, Fahey JL, Sands H, et al. Ebola virus: immune mechanisms of protection and vaccine development. Biol Res Nurs 2003 Apr;4(4):276-81

O'Brien KK, Higdon NL, Halverson JJ. Recognition and management of bioterrorism infections. Am Fam Physician 2003 May 1;67(9):1927-34

Okware SI, Omaswa FG, Zaramba S, et al. An outbreak of Ebola in Uganda. Trop Med Int Health 2002 Dec;7(12):1068-75

Omilabu SA, Badaru SO, Okokhere P, et al. Lassa fever, Nigeria, 2003 and 2004. (Letter) Emerg Infect Dis 2005 Oct;11(10):1642-4

Onyango CO, Grobbelaar AA, Gibson VF, et al. Yellow fever outbreak, southern Sudan, 2003. Emerg Infect Dis 2004 Sep;10(9):1668-70

Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007 Jan 19;3(1):e9

Paddock CD, Nicholson WL, Bhatnagar J, et al. Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin Infect Dis 2006 Jun 1;42(11):1527-35

Padula P, Martinez VP, Bellomo C, et al. Pathogenic hantaviruses, northeastern Argentina and Paraguay. Emerg Infect Dis 2007 Aug;13(8):1211-4

Palacios G, Quan P-L, Jabado OJ, et al. Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis 2007;13(1) (published online Dec 6)

Papa A, Bozovic B, Pavlidou V, et al. Genetic detection and isolation of Crimean-Congo hemorrhagic fever virus, Kosovo, Yugoslavia. Emerg Infect Dis 2002 Aug;8(8)

Papa A, Christova I, Papadimitriou E, et al. Crimean-Congo hemorrhagic fever in Bulgaria. Emerg Infect Dis 2004 Aug;10(8):1465-7

Papa A, Drosten C, Bino S, et al. Viral load and Crimean-Congo hemorrhagic fever. (Letter) Emerg Infect Dis 2007 May;13(5) (published online Apr 18)

Parrino J, Hotchkiss RS, Bray M. Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections. Emerg Infect Dis 2007 Feb;13(2) (published online Jan 23)

Pattyn SR, ed. Proceedings of an international colloquium on Ebola virus infection and other haemorrhagic fevers. Antwerp, Belgium, Dec 6-8, 1977

Pavri K. Clinical, clinicopathologic, and hematologic features of Kyasanur Forest disease. Rev Infect Dis 1989;11(suppl 4):S854-S859

Paweska JT, Burt FJ, Swanepoel R. Validation of IgG-sandwich and IgM-capture ELISA for the detection of antibody to Rift Valley fever virus in humans. J Virol Methods 2005 Mar;124(1-2):173-81

Peters CJ, Johnson ED, Jarhling PB, et al. Filoviruses. In: Emerging viruses. Morse S, ed. New York, NY: Oxford University Press, 1991:159-75

Peters CJ, Kuehne RW, Mercado RR, et al. Hemorrhagic fever in Cochabamba, Bolivia, 1971. Am J Epidemiol 1974;99:425-33

Peters CJ, LeDuc JW. An introduction to Ebola: the virus and the disease. J Infect Dis 1999 Feb;179(suppl 1):ix-xvi

Peters CJ, Reynolds JA, Slone TW, et al. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res 1986;6:285-97

Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic fevers. Crit Care Med 2002 May;30(5 Suppl):S268-73

Peters CJ. California encephalitis, hantavirus pulmonary syndrome, and Bunyavirid hemorrhagic fevers. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Ed 6. New York: Churchill Livingstone, 2005:2086-90

Peters CJ. Lymphocytic choriomeningitis virus, Lassa virus, and the South American hemorrhagic fevers. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Ed 6. New York: Churchill Livingstone, 2005:2090-8

Peters CJ. Marburg and Ebola - arming ourselves against the deadly filoviruses. N Engl J Med 2005 Jun 23;352(25):2571-3

Peters CJ. Marburg and Ebola virus hemorrhagic fevers. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. Ed 6. New York: Churchill Livingstone, 2005:2057-60

Peterson AT, Bauer JT, Mills JN. Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis 2004 Jan 10(1):40-7

Pittman PR, Liu CT, Cannon TL, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans. Vaccine 1999;18:181-9

Pourrut X, Kumulungui B, Wittman T, et al. The natural history of Ebola virus in Africa. Microbes and Infection 2005 Jun;7(7-8):1005-14

Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008 (published online Jul 3)

Radoshitzky SR, Abraham J, Spiropoulou CF, et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 2007 Mar 1;446(7131):92-6

Raftery MJ, Kraus AA, Ulrich R, et al. Hantavirus infection of dendritic cells. J Virol 2002 Nov;76(21):10724-33

Rahman M, Rahman K, Siddque AK, et al. First outbreak of Dengue hemorrhagic fever, Bangladesh. Emerg Infect Dis 2002 Jul;8(7)

Rico-Hesse R. Dengue virus evolution and virulence models. Clin Infect Dis 2007 Jun 1;44(11):1462-6

Ringot D, Durand J-P, Tulou H, et al. Rift Valley fever in Chad. Emerg Infect Dis 2004 May;10(5)

Roels TH, Bloom AS, Buffington J, et al. Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo: risk factors for patients without a reported exposure. J Infect Dis 1999 Feb;179(Suppl 1):S92-S97

Roukens AH, Vossen AC, Bredenbeek PJ, et al. Intradermally administered yellow fever vaccine at reduced doses induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 2008 Apr 23;3(4):e1993

Rouquet P, Froment J-M, Bermejo M, et al. Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo, 2001-2003. Emerg Infect Dis 2005 Feb;11(2)

Saijo M, Georges-Courbot MC, Marianneau P, et al. Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever. Clin Vaccine Immunol 2007 Sep;14(9):1182-9

Sall AA, Macondo EA, Sene OK, et al. Use of reverse transcriptase PCR in early diagnosis of rift valley Fever. Clin Diagn Lab Immunol 2002;9(3):713-5

Sanchez A, Lukwiya M, Bausch D, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol 2004 Oct 1;78(19):10370-7

Schnittler HJ, Feldmann H. Viral hemorrhagic fever?a vascular disease? Thromb Haemost 2003 Jun;89(6):967-72

Sewell DL. Laboratory safety practices associated with potential agents of biocrime or bioterrorism. J Clin Microbiol 2003 Jul;41(7):2801-9

Shoemaker J, Boulianne C, Vincent MJ, et al. Genetic analysis of viruses associated with emergence of Rift Valley fever in Saudi Arabia and Yemen, 2000-01. Emerg Infect Dis 2002;8(12)

Siqueira JB Jr, Martelli CM, Coelho GE, et al. Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerg Infect Dis 2005 Jan;11(1):48-53

Smego RA, Sarwari AR, Siddiqui AR. Crimean-Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis 2004 Jun 15;38(12):1731-5

Smith CE, Tom T, Sasaki J, et al. Dengue risk among visitors to Hawaii during an outbreak. Emerg Infect Dis 2005 May;11(5)

Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, et al. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Ped Infect Dis J 2007 Apr;26(4):283-90

Sullivan N, Yang ZY, Nable GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol 2003 Sep;77(18):9733-7

Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003 Aug 7;424(6949:681-3

Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006 Jun;3(6)

Sullivan NJ, Geisbert TW, Giesbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. (Letter) Nature 2003 Aug 7;424:681-4

Sundar K, Boesen A, Coico R. Computational prediction and identification of HLA-A2.1-specific Ebola virus CTL epitopes. Virology 2007 Apr 10;360(2):257-63

Swanepoel R, Smit SB, Rollin PE, et al. Studies of reservoir hosts for Marburg virus. Emerg Infect Dis 2007 Dec;13(12):1847-50 (published online Oct 23)

Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 2008 Mar;15(3):460-7

Takada A, Ebihara H, Jones S, et al. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007 Jan 22;25(6):993-9

Takada A, Ebihara H, Jones S, et al. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007 Jan 22;25(6):993-9

Tarantola A, Nabeth P, Tattevin P, et al. Lookback exercise with imported Crimean-Congo Hemorrhagic fever, Senegal and France. Emerg Infect Dis 2006 Sep;12(9):1424-6

Ter Meulen J, Sakho M, Koulemou K, et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever.

Thammapalo S, Nagao Y, Sakamoto W, et al. Relationship between transmission intensity and incidence of dengue hemorrhagic fever in Thailand. PLoS Negl Trop Dis 2008 Jul 16;(27):e263

Towner JS, Pourrut X, Albarino CG, et al. Marburg virus infection detected in a common African bat. PLoS ONE 2007 Aug 22;2(8):e764

Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004 Apr;78(8):4330-41

Van der Lugt JJ, Coetzer JA, Smit MM. Distribution of viral antigen in tissues of new-born lambs infected with Rift Valley fever virus. Onderstepoort J Vet Res 1996 Dec;63(4):341-7

Vasconcelos PFC, Bryant JE, Travassos da Rosa APA, et al. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis 2004 Sep;10(9):1578-84

Vogel G. Scientists say Ebola has pushed Western gorillas to the brink. Science 2007 Sep 14;317(5844):1484

Vogel G. Tracking Ebola's deadly march among wild apes. Science Dec 8;314(5805):1522-23

Wang D, Raja NU, Trubey CM, et al. Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J Virol 2006 Mar;80(6):2738-46

Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci 2003 Dec 23;100(26):15889-94

Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006 Jan;2(1)

Warfield KL, Swenson DL, Olinger GG, et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PloS Pathog 2006 Jan;2(1):5-13

Weber DJ, Rutala WA. Risks and prevention of nosocomial transmission of rare zoonotic diseases. Clin Infect Dis 2001;32:446-56

Weidmann M, Muhlberger E, Hufert FT. Rapid detection protocol for filoviruses. J Clin Virol 2004 May;30(1):94-9

WHO. Disease outbreak news: Yellow fever

WHO. Ebola haemorrhagic fever in the Republic of the Congo. Jun 16, 2005

WHO. Ebola haemorrhagic fever in Zaire, 1976. Report of an International Commission. Bull World Health Org 1978;56(2);271-93

WHO. Fact sheets: Ebola hemorrhagic fever.

WHO. Fact sheets: Lassa hemorrhagic fever. Dec 2001.

WHO. Guidelines for the collection of clinical specimens during field investigation of outbreaks

WHO. Marburg haemorrhagic fever: situation updates

WHO. Marburg virus disease in Angola: update. Mar 23, 2005

WHO. Viral hemorrhagic fevers: report of a WHO expert committee, 1984

WHO. WHO announces end of Ebola outbreak in southern Sudan. Aug 7, 2004

WHO. WHO recommended guidelines for epidemic preparedness and response: Ebola haemorrhagic fever (EHF). WHO/EMC/DIS/97.7

WHO. Yellow fever. Immunologic Basis for Immunization Series, module 8. 1993

WHO: Ebola Haemorrhagic Fever - Disease Outbreaks Archive Scroll to individual diseases

Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J Infect Dis 2007 Apr 15;195(8):1089-96

Wilson ME, Chen L, Barnett ED. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep 2004 Feb;6(1):43-2

Wolfel R, Paweska JT, Petersen N, et al. Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients. Emerg Infect Dis 2007 Jul;13(7):1097-100

Woods CW, Karpati AM, Grein T, et al. An outbreak of Rift Valley fever in northeastern Kenya, 1997-98. Emerg Infect Dis 2002 Feb;8(2).

Zaki SR, Kilmarx PH. Ebola virus hemorrhagic fever. In: Nelson AM, Horsburgh CR, eds. Pathology of emerging infections. Washington, DC: American Society of Microbiology Press, 1997:299-312

Zaki SR, Shieh WJ, Greer PW, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999 Feb;179(Suppl 1):S36-S47

Zampieri CA, Fortin JF, Nolan GP, et al. The ERK mitogen-activated protein kinase pathway contributes to Ebola virus glycoprotein-induced cytotoxicity. J Virol 2007 Feb;81(3):1230-40